what is the soma

cheap phentermine cheap drugs

Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.S. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers. The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. what is the soma Serum creatinine levels increase by about 0. what is the soma The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009. purchase tramadol without prescription

The FDA approval is based on five international, multi-center, randomized clinical trials involving nearly 6,300 patients. To ensure the use of Multaq in the appropriate patient population, sanofi-aventis U. The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. The efficacy and safety of Multaq 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq. Multaq should not be coadministered with strong CYP 3A inhibitors or medicinal products that prolong the QT interval. what is the soma The risk mitigation program consists of a Communication Plan for HCPs, a medication guide for patients and post-marketing surveillance. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. what is the soma The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation. soma online description chemistry ingredients blackbox

Multaq is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted. "Sanofi-aventis’ commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash. Multaq is also contraindicated in second- or third-degree atrioventricular (AV) block or sick sinus syndrome (except when used in conjunction with a functioning pacemaker), bradycardia <50 bpm, QTc Bazett interval greater than or equal to 500 ms and severe hepatic impairment.S. what is the soma The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. what is the soma Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL. The elevation has a rapid onset, reaches a plateau after 7 days and is reversible after discontinuation.